Documente Academic
Documente Profesional
Documente Cultură
Sulfonylureas
Sulfonylureas
Insulinotropic agent Oral Hypoglycemic agent Acidic in nature Sulfonamide structure analogue but have no antibacterial activity
Sulfonylurea
Sulfonamide
Sulfonylurea: Generation
12,00 sulfonylureas have been synthesized 10 compounds are used world wide to reduce blood glucose levels The sulfonylureas are divided into two groups or generations of agents Least expensive class of medication
Sulfonylurea: Generation
The first group of sulfonylureas includes tolbutamide, acetohexamide, tolazamide, and chlorpropamide. A second, more potent generation of hypoglycemic sulfonylureas has emerged, including glyburide (glibenclamide), glipizide, gliclazide, and glimepiride.
Ref: Goodman & Gilman's The Pharmacologic Basis of Therapeutics - 11th Ed. (2006)
Sulfonylurea: Generation
Second (and third generation) sulfonylureas are 100 times more potent than first generation. Although their half-lives are short (3 to 5 hours), their hypoglycemic effects are evident for 12 to 24 hours (specific reason unknown). Have large side chain in structure. More lipid soluble.
Sulfonylurea: SAR
General structure
All members of this class of drugs are substituted arylsulfonylureas R1 aliphatic group (acetyl, amino, chloro, etc.) Affect duration of action of drug It should be in para position
Biotransformation of tolbutamide
Sulfonylurea: SAR
The second generation agents are more potent than the first generation agents. It is believed that this is because of a specific distance between the nitrogen atom of the substituent (R1) and the sulfonamide nitrogen atom.
Glipizide
Sulfonylurea: SAR
R2 group impart lipophilic properties to the molecule R2 may be: Aliphatic moiety (3-6 carbon: max activity) or An alicyclic or heterocyclic ring (5-7 carbon: max activity) Aryl group: toxic compound
Mechanism of action:
Kir
Kir 6.2 Kir 6.2
SUR 1 SUR 2A
SUR 2B
Kir 6.2
Glibenclamide
140 kDa
Cell membrane
65 kDa
Glimepiride
Glimepiride: 65 kDa
65 kDa component absent in cardiovascular system Safer to use glimepiride in patients with a higher cardiovascular risk (CAD)
Oral Antidiabetics
Nonsulfonylureas
Meglitinides
Insulinotropic agent Acidic compounds Nonsulfonylurea oral hypoglycemic agent Commonly used are: Repaglinide, Nateglinide (known as Metaglinides) MA similar to sulfonylurea but not clear whether the drug bind with SUR1
Repaglinide
This agent is a derivative of benzoic acid Its structure is unrelated to that of the sulfonylureas
Nateglinide
Derived from D-phenylalanine Its structure is unrelated to that of the sulfonylureas
More rapid but less sustained secretion of insulin than other Produce fewer episodes of hypoglycemia than most other
Meglitinides vs Sulfonylureas
Causes much faster insulin production than the sulfonylurea Short duration of action (Half life: less than an hour) compared to sulfonylureas (several hours) Less risk of hypoglycemia and weight gain Devoid of side effects of sulfa compounds
Oral Antidiabetics
Biguanide
Biguanides
Guanidine derivatives Guanidine Antihyperglycemic drugs Most common: metformin, phenformin Can produce lactic acidosis Phenformin: 2 cases per 1000 users Metformin: 0-0.084 cases per 1000 users Lactic acidosis is an uncommon but potentially fatal adverse effect.
Lactic acidosis
Lactic acidosis is when lactic acid builds ups in the bloodstream faster than it can be removed. Lactic acid is produced when oxygen levels in the body drop. (vigorous exercise) Cells are forced to metabolize glucose anaerobically, which leads to lactate formation. (biguanides)
Biguanides
Metformin
Phenformin
Biguanides: Functions
No effect on pancreatic beta cell.
- glucose uptake and utilization (glycolysis) by muscle cells (peripheral tissue) with lactic acidosis - glucose production by liver (Gluconeogenesis)
- glucose (+ Vitamin B12) uptake from intestine
Structural properties
R is aliphatic (Buformin) or aromatic (Phenformin) (exp. metformin) R usually H, may be alkyl group (etoformin) R usually H, often large group (phenfosformin)
Etoformin
Oral Antidiabetics
Thiazolidinediones
Thiazolidinediones
Known as glitazones or insulin resistance reducers First drug: Troglitazone (withdrawn due to liver toxicity) Two glitazones are available: pioglitazone and rosiglitazone Both are acidic compounds
Pioglitazone
Rosiglitazone
Chirality
Both has one chiral center thus has two isomers Compounds are used as racemic mixture Functionally indistinguishable: due to interconversion in in vivo
Mechanism of action
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor molecules Thiazolidinediones are selective agonists for gamma form of PPARs When activated, the receptor migrates to the DNA, activating transcription of a number of specific genes.
Mechanism of action
Insulin resistance is decreased Increase the synthesis of certain proteins involved in glucose metabolism
Oral Antidiabetics
-Glucosidase Inhibitors
-Glucosidase Inhibitors
Enzyme present in brush border of small intestine Split dietary carbohydrate and helps in absorption Do not increase insulin secretion, no involvement in hypoglycemia No or little effect on fasting blood glucose Have to use preprandially (as the drugs are competitive inhibitors )
-Glucosidase Inhibitors
Reduce postprandial hyperininsulinemia Do not promote weight gain Used as adjunct therapy for obese patient with diabetes insufficiently controlled by diet and other classical antidiabetic drugs. Example: Acarbose, Miglitol and Voglibose
Mechanism of action
Competitive inhibitor of the enzyme. This enzyme recognizes specific residues in the polymeric sugar chain and hydrolyses the interglycoside linkage. The membrane-bound intestinal glucosidases hydrolyze oligosaccharides (typically four to ten), trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine.
(Table sugar)
Mechanism of action
Low dose: Delay absorption High dose: Inhibit absorption Inhibition of these enzyme systems reduces the rate of digestion of carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules.
Non-reducing end
Reducing end
Acarbose
Naturally occurring oligosaccharide (tetrasaccharide) Competitive inhibitor Enzyme attempts to hydrolyze but failed Has a 105 fold higher affinity than typical substrate Minimally absorb (0.5-1.7%) Produce flatulence and bloating in 60% cases
4 5
Non-reducing end
Miglitol
Has similar structure to a sugar (resembles a monosaccharide) Second generation -Glucosidase inhibitor
Competitive inhibitor
Completely absorb at low dose, but not metabolized and excreted through kidney
Miglitol
Glucose